BR9713492A - ésteres de ácido graxo de ácido glicólico e seus sais como realçadores de permeação - Google Patents

ésteres de ácido graxo de ácido glicólico e seus sais como realçadores de permeação

Info

Publication number
BR9713492A
BR9713492A BR9713492-9A BR9713492A BR9713492A BR 9713492 A BR9713492 A BR 9713492A BR 9713492 A BR9713492 A BR 9713492A BR 9713492 A BR9713492 A BR 9713492A
Authority
BR
Brazil
Prior art keywords
fatty acid
glycolic acid
salts
glycolic
incorporated
Prior art date
Application number
BR9713492-9A
Other languages
English (en)
Inventor
Srinivasan Venkateshwaran
David Fikstad
Sonal R Patel
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Publication of BR9713492A publication Critical patent/BR9713492A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: <B>"ESTERES DE áCIDO GRAXO DE áCIDO GLICóLICO E SEUS SAIS COMO REALçADORES DE PERMEAçãO"<D>. Um sistema de liberação transdérmica de medicamento, que acentua a liberação do medicamento, compreende uma composição contendo, como um reforçador, um ou mais C~ 5~ a C~ 21~ ésteres de ácido graxo de ácido glicórico e seus sais. Estas composições são compostas de uma quantidade segura de um permeante farmacêutico ativo contido em num veículo de intensificação da penetração, compreendendo de 0,25 a 50% em peso do acentuador de éster de ácido graxos em um veículo portador adequado. Estes reforçadores de éster de ácido glicórico de ácidos graxos podem ser usados em vários veículos portadores para acentuar a liberação transdérmica dos permeantes ativos, ou na forma livre ou usado em um dispositivo oclusivo, particularmente em um emplastro transdérmico na forma de matriz ou de reservatório. Quando usado na forma de emplastro de matriz, os reforçadores de éster de ácido glicórico de ácidos graxos e os permeantes são incorporados em um adesivo biocompatível. quando usado em um emplastro tipo reservatório, o permeante e os reforçadores de éster de ácido glicórico de ácidos graxos são incorporados em um fluido portador de viscosidade controlada, tal como um gel ou um unguento, preferivelmente contendo um alcanol inferior e água. Na forma livre o reforçador e o permeante podem ser incorporados em um unguento, loção, creme ou formulação similar.
BR9713492-9A 1996-10-30 1997-10-29 ésteres de ácido graxo de ácido glicólico e seus sais como realçadores de permeação BR9713492A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74107196A 1996-10-30 1996-10-30
PCT/US1997/019600 WO1998018416A1 (en) 1996-10-30 1997-10-29 Fatty acid esters of glycolic acid and its salts as permeation enhancers

Publications (1)

Publication Number Publication Date
BR9713492A true BR9713492A (pt) 2000-02-29

Family

ID=24979259

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9713492-9A BR9713492A (pt) 1996-10-30 1997-10-29 ésteres de ácido graxo de ácido glicólico e seus sais como realçadores de permeação
BR9712474-5A BR9712474A (pt) 1996-10-30 1997-10-29 •steres de ácido graxo de sais de ácido láctico como melhoradores de permeação

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9712474-5A BR9712474A (pt) 1996-10-30 1997-10-29 •steres de ácido graxo de sais de ácido láctico como melhoradores de permeação

Country Status (10)

Country Link
US (2) US5952000A (pt)
EP (2) EP0942697A1 (pt)
JP (2) JP2001503749A (pt)
KR (2) KR20000035800A (pt)
CN (2) CN1231592A (pt)
AU (2) AU718811B2 (pt)
BR (2) BR9713492A (pt)
CA (2) CA2263300A1 (pt)
WO (2) WO1998018416A1 (pt)
ZA (2) ZA979765B (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
IL136042A (en) 1997-11-10 2005-12-18 Cellegy Pharma Inc Alcohol-containing composition for topical application
US20040067212A1 (en) * 1998-03-11 2004-04-08 Kabushiki Kaisha Soken Skin conditioner
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
JP2003506462A (ja) * 1999-06-25 2003-02-18 ダーハム ファーマシューティカルズ リミテッド 皮膚浸透剤を含む局所処方物およびその使用
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040037872A1 (en) * 2000-09-18 2004-02-26 Liebschutz Isabelle Francine Tropical composition
DE60141596D1 (de) * 2000-10-23 2010-04-29 Euro Celtique Sa Transdermales system zur verabreichung von loratadin und dessen verwendung
JP2004537516A (ja) * 2001-05-11 2004-12-16 オラセンス リミテッド アンチセンス浸透促進剤
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
SG120911A1 (en) * 2002-02-25 2006-04-26 Nitto Denko Corp Aqueous dispersion type pressure-sensitive adhesive composition and pressure-sensisive adhesive product
US7396868B2 (en) 2002-02-25 2008-07-08 Nitto Denko Corporation Aqueous dispersion type pressure-sensitive adhesive composition and pressure-sensitive adhesive product
KR101407131B1 (ko) 2002-06-10 2014-06-19 유로-셀티크 소시에떼 아노뉨 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템
US7099713B2 (en) 2002-06-28 2006-08-29 Battelle Memorial Institute Skin conduction and transport systems
US20040126323A1 (en) * 2002-08-20 2004-07-01 Ihor Shevchuk Transdermal dosage form comprising an active agent and a salt and free-base form of an adverse agent
US20040127531A1 (en) * 2002-11-21 2004-07-01 Lu Guang Wei Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor
US20040126415A1 (en) * 2002-11-21 2004-07-01 Lu Guang Wei Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor
FR2851470B1 (fr) 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
RS20050812A (en) * 2003-04-30 2007-12-31 Purdue Pharma L.P., Tamper resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
US7105263B2 (en) * 2003-12-30 2006-09-12 Samsung Electronics Company Dry toner comprising encapsulated pigment, methods and uses
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
ZA200803087B (en) 2005-10-12 2009-11-25 Unimed Pharmaceuticals Llc Improved testosterone gel and method of use
EP2007397B1 (en) * 2006-04-07 2013-07-24 Merrion Research III Limited Solid oral dosage form containing an enhancer
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
FR2905601A1 (fr) * 2006-09-11 2008-03-14 Innoderm Sarl Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques.
JP5209433B2 (ja) * 2007-10-19 2013-06-12 日東電工株式会社 貼付製剤
TW200950799A (en) * 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of GnRH related compounds and processes of preparation
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
US20130274352A1 (en) * 2009-04-14 2013-10-17 The Regents Of The University Of California Oral Drug Devices and Drug Formulations
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
AU2010339907A1 (en) 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
CA2791882C (en) 2010-03-12 2018-04-10 Monsanto Technology Llc Agrochemical gel compositions
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
CA2819234A1 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
WO2018063876A1 (en) * 2016-09-30 2018-04-05 Alpha To Omega Pharmaceutical Consultants, Inc. Transdermal and/or topical delivery systems comprising cetirizine dihydrochloride
US20220113647A1 (en) * 2019-06-06 2022-04-14 Hewlett-Packard Development Company, L.P. Electrostatic ink composition
CA3155267A1 (en) 2019-11-06 2021-05-14 Thomas Hnat Topical formulations of cyclooxygenase inhibitors and their use
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551154A (en) * 1966-12-28 1970-12-29 Ferrania Spa Light sensitive article comprising a quinone diazide and polymeric binder
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3728447A (en) * 1970-03-03 1973-04-17 Patterson Co C Fatty acid lactylates and glycolates for conditioning hair
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4006218A (en) * 1974-07-08 1977-02-01 Johnson & Johnson Potentiated medicaments
US4164190A (en) * 1976-10-29 1979-08-14 Newman Dwight C Seed planting method for cereal grains and grasses
US4198311A (en) * 1978-07-03 1980-04-15 C. J. Patterson Company Skin conditioning toilet bar
FR2462192B1 (fr) * 1979-08-02 1986-08-01 Oreal Emulsions du type " eau-dans-l'huile " utilisables comme supports cosmetiques ou excipients pharmaceutiques
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4822601A (en) * 1987-03-13 1989-04-18 R.I.T.A. Corporation Cosmetic base composition with therapeutic properties
US4761279A (en) * 1987-03-31 1988-08-02 Eastman Kodak Company Shaving cream formulations
US4820720A (en) * 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
US4983395A (en) * 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4888354A (en) * 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
US4960814A (en) * 1988-06-13 1990-10-02 Eastman Kodak Company Water-dispersible polymeric compositions
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
GB8828014D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5154122A (en) * 1989-10-20 1992-10-13 Sol Goldschmidt Shipping device for suspended piece goods
IT1243745B (it) * 1990-10-17 1994-06-21 Vectorpharma Int Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione.
US5314694A (en) * 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
US5202125A (en) * 1990-12-10 1993-04-13 Theratech, Inc. Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5227169A (en) * 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5212199A (en) * 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
GB9222335D0 (en) * 1992-10-23 1992-12-09 Unilever Plc Acyl lactylates as skin elasticity enhancing agents
BR9407231A (pt) * 1993-08-13 1996-09-24 Unilever Nv Uso de um derivado de hidróxi alcanoato processo para aplicar um 2-hidróxi alcanoato à epiderme e composição adequada para ser topicamente aplicada à pele
IL109012A (en) * 1994-03-17 1998-09-24 Fischer Pharma Ltd Skin whitening composition comprising glycyrrhyza glabra and hydroxy acids
WO1996002903A1 (en) * 1994-07-18 1996-02-01 General Railway Signal Corporation Smart bolt device having communications system in separate housing from bolt
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates

Also Published As

Publication number Publication date
WO1998018417A1 (en) 1998-05-07
EP0971662A1 (en) 2000-01-19
AU5157098A (en) 1998-05-22
US5912009A (en) 1999-06-15
JP2001503749A (ja) 2001-03-21
CN1231592A (zh) 1999-10-13
KR20000035800A (ko) 2000-06-26
JP2001503062A (ja) 2001-03-06
AU5240998A (en) 1998-05-22
ZA979765B (en) 1998-05-22
AU717183B2 (en) 2000-03-16
BR9712474A (pt) 1999-10-26
KR20000035801A (ko) 2000-06-26
EP0942697A1 (en) 1999-09-22
AU718811B2 (en) 2000-04-20
CA2263300A1 (en) 1998-05-07
ZA979771B (en) 1998-05-22
CA2263334A1 (en) 1998-05-07
WO1998018416A1 (en) 1998-05-07
CN1231593A (zh) 1999-10-13
US5952000A (en) 1999-09-14

Similar Documents

Publication Publication Date Title
BR9713492A (pt) ésteres de ácido graxo de ácido glicólico e seus sais como realçadores de permeação
ES2137993T3 (es) La utilizacion de glicerina para moderar el aporte transdermico de medicamentos.
DE69833000T2 (de) Bio-klebemittelzusammensetzungen
ES2201434T3 (es) Sistema terapeutico transdermal para la administracion de hormonas.
JP2001513543A (ja) 皮膚への局所適用のための非ステロイド性抗炎症薬製剤
BR9907666A (pt) Preparações tópicas anìdricas para a pele
ES2089011T3 (es) Excipiente lipidico de administracion nasal y aplicacion topica.
BR0108461A (pt) Composição cosmética de fase única transparente
US20090123504A1 (en) Olive oil formulation for pain relief
TW408020B (en) Two-phase composition for topical, application
HUP0302452A2 (hu) Prosztaglandin E1-et tartalmazó topikus gyógyászati készítmények
ES2650251T3 (es) Composición farmacéutica tópica
ES2378408T3 (es) Composición de un gel que forma una película para el cuidado de heridas o de la piel
ES2219665T3 (es) Parche de escopolamina.
ITMI990834A1 (it) Cerotto per uso topico eparina e diclofenac
AR064262A1 (es) Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato
US20070020325A1 (en) Hydrogel composition
PE17897A1 (es) Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano
SK126093A3 (en) Lanoline derivatives as a penetration-promoting substances
ES2222860T3 (es) Parche adhesivo fino tratado con betametasona y acido hialuronico para el tratamiento de la soriasis, dermatitis y dermatosis.
JP3040427B2 (ja) 神経痛治療用アスピリン含有軟膏組成物
BR0108455A (pt) Composição cosmética de uma fase, transparente
JP2020518653A (ja) 局所製剤及び方法
US20200237657A1 (en) Nasal moisturizer
TW202239430A (zh) 外用劑組合物

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]